| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| TNF-Related Apoptosis-Inducing Ligand | 19 | 2014 | 65 | 1.670 |
Why?
|
| Apoptosis | 26 | 2015 | 1641 | 1.460 |
Why?
|
| Urinary Bladder Neoplasms | 8 | 2013 | 138 | 1.330 |
Why?
|
| Adenoviridae | 14 | 2013 | 295 | 1.090 |
Why?
|
| Genetic Therapy | 11 | 2013 | 291 | 1.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 14 | 2008 | 626 | 0.980 |
Why?
|
| Prostatic Neoplasms | 13 | 2011 | 778 | 0.970 |
Why?
|
| Pyridines | 6 | 2015 | 261 | 0.890 |
Why?
|
| Ceramides | 9 | 2015 | 578 | 0.800 |
Why?
|
| Membrane Glycoproteins | 10 | 2006 | 370 | 0.790 |
Why?
|
| fas Receptor | 5 | 2010 | 54 | 0.650 |
Why?
|
| Neoplasms | 7 | 2021 | 1667 | 0.620 |
Why?
|
| Doxorubicin | 7 | 2007 | 231 | 0.590 |
Why?
|
| Colonic Neoplasms | 4 | 2015 | 299 | 0.590 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2006 | 216 | 0.550 |
Why?
|
| Benzenesulfonates | 3 | 2010 | 30 | 0.530 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2010 | 40 | 0.530 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 3 | 2015 | 201 | 0.530 |
Why?
|
| Antineoplastic Agents | 8 | 2009 | 1070 | 0.520 |
Why?
|
| Sphingolipids | 3 | 2021 | 337 | 0.520 |
Why?
|
| Hydroxamic Acids | 4 | 2010 | 84 | 0.510 |
Why?
|
| Gene Transfer Techniques | 3 | 2013 | 173 | 0.480 |
Why?
|
| Apoptosis Regulatory Proteins | 9 | 2009 | 100 | 0.460 |
Why?
|
| Cell Line, Tumor | 15 | 2013 | 1851 | 0.450 |
Why?
|
| Saccule and Utricle | 2 | 2013 | 7 | 0.430 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 9 | 2009 | 18 | 0.420 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2015 | 331 | 0.400 |
Why?
|
| Genetic Vectors | 9 | 2013 | 312 | 0.390 |
Why?
|
| Signal Transduction | 11 | 2014 | 2689 | 0.390 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 4 | 2015 | 140 | 0.380 |
Why?
|
| Adamantane | 2 | 2015 | 40 | 0.350 |
Why?
|
| Tumor Cells, Cultured | 12 | 2015 | 852 | 0.340 |
Why?
|
| Oxidoreductases | 3 | 2015 | 117 | 0.320 |
Why?
|
| Receptors, Virus | 2 | 2009 | 20 | 0.310 |
Why?
|
| Herpesvirus 8, Human | 2 | 2014 | 24 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2010 | 468 | 0.300 |
Why?
|
| Protein Biosynthesis | 4 | 2009 | 181 | 0.290 |
Why?
|
| Fas Ligand Protein | 6 | 2010 | 64 | 0.290 |
Why?
|
| Calcium | 3 | 2010 | 929 | 0.280 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2009 | 332 | 0.280 |
Why?
|
| Cell Cycle | 3 | 2021 | 312 | 0.270 |
Why?
|
| Transduction, Genetic | 4 | 2011 | 81 | 0.270 |
Why?
|
| Humans | 42 | 2021 | 68618 | 0.270 |
Why?
|
| STAT6 Transcription Factor | 1 | 2014 | 11 | 0.250 |
Why?
|
| Neoplasm Proteins | 2 | 2009 | 307 | 0.250 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2015 | 62 | 0.240 |
Why?
|
| Virus Latency | 1 | 2014 | 10 | 0.240 |
Why?
|
| Acid Ceramidase | 1 | 2015 | 85 | 0.240 |
Why?
|
| RANK Ligand | 1 | 2014 | 73 | 0.240 |
Why?
|
| Polymers | 2 | 2013 | 244 | 0.230 |
Why?
|
| Sulfhydryl Compounds | 1 | 2014 | 73 | 0.230 |
Why?
|
| Phospholipases A | 4 | 1998 | 41 | 0.230 |
Why?
|
| Lymphoma, Primary Effusion | 1 | 2013 | 7 | 0.230 |
Why?
|
| Osteoblasts | 1 | 2014 | 99 | 0.230 |
Why?
|
| Urinary Catheterization | 1 | 2013 | 27 | 0.230 |
Why?
|
| Hair Cells, Auditory, Inner | 1 | 2013 | 19 | 0.220 |
Why?
|
| Aminoglycosides | 1 | 2013 | 54 | 0.220 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2014 | 132 | 0.220 |
Why?
|
| Oxidative Stress | 3 | 2011 | 718 | 0.220 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2013 | 42 | 0.220 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2014 | 135 | 0.220 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2014 | 183 | 0.220 |
Why?
|
| Membrane Proteins | 2 | 2015 | 617 | 0.210 |
Why?
|
| Mice | 14 | 2015 | 8474 | 0.210 |
Why?
|
| Transgenes | 5 | 2013 | 92 | 0.210 |
Why?
|
| Mitochondria | 2 | 2014 | 643 | 0.210 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2014 | 266 | 0.210 |
Why?
|
| Animals | 19 | 2015 | 20881 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2015 | 756 | 0.200 |
Why?
|
| Hair Cells, Auditory | 1 | 2012 | 60 | 0.200 |
Why?
|
| Immunity, Innate | 2 | 2011 | 156 | 0.200 |
Why?
|
| Urogenital Neoplasms | 1 | 2011 | 9 | 0.200 |
Why?
|
| Autophagy | 2 | 2010 | 208 | 0.190 |
Why?
|
| Peptide Elongation Factor 2 | 2 | 2009 | 14 | 0.190 |
Why?
|
| Cell Proliferation | 5 | 2015 | 1174 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 3 | 2005 | 511 | 0.190 |
Why?
|
| Adenoviruses, Human | 2 | 2009 | 12 | 0.190 |
Why?
|
| Enzyme Activation | 7 | 2010 | 791 | 0.190 |
Why?
|
| Interleukin-15 | 1 | 2011 | 66 | 0.190 |
Why?
|
| Lactams, Macrocyclic | 1 | 2010 | 7 | 0.180 |
Why?
|
| Benzoquinones | 1 | 2010 | 13 | 0.180 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 69 | 0.180 |
Why?
|
| src-Family Kinases | 1 | 2010 | 91 | 0.180 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 206 | 0.170 |
Why?
|
| Caspases | 6 | 2006 | 194 | 0.170 |
Why?
|
| Superoxides | 1 | 2009 | 70 | 0.170 |
Why?
|
| MicroRNAs | 1 | 2014 | 447 | 0.170 |
Why?
|
| Epitopes | 1 | 2009 | 146 | 0.160 |
Why?
|
| Interleukins | 1 | 2009 | 79 | 0.160 |
Why?
|
| Down-Regulation | 5 | 2010 | 447 | 0.160 |
Why?
|
| Boronic Acids | 1 | 2009 | 40 | 0.160 |
Why?
|
| Antioxidants | 1 | 2011 | 304 | 0.160 |
Why?
|
| eIF-2 Kinase | 1 | 2009 | 49 | 0.160 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2009 | 79 | 0.160 |
Why?
|
| Drug Synergism | 5 | 2009 | 260 | 0.160 |
Why?
|
| Pyrazines | 1 | 2009 | 46 | 0.160 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2006 | 116 | 0.160 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 1293 | 0.160 |
Why?
|
| Prostate | 2 | 2006 | 116 | 0.160 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 434 | 0.160 |
Why?
|
| Carcinoma | 1 | 2010 | 215 | 0.160 |
Why?
|
| Antigens, CD | 1 | 2009 | 230 | 0.160 |
Why?
|
| Cell Survival | 2 | 2009 | 901 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2009 | 110 | 0.160 |
Why?
|
| Caspase 3 | 1 | 2009 | 233 | 0.150 |
Why?
|
| Reactive Oxygen Species | 4 | 2011 | 499 | 0.150 |
Why?
|
| Cell Nucleus | 1 | 2009 | 305 | 0.150 |
Why?
|
| Green Fluorescent Proteins | 4 | 2013 | 200 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 597 | 0.150 |
Why?
|
| Depsipeptides | 1 | 2006 | 21 | 0.140 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2003 | 32 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 235 | 0.140 |
Why?
|
| bcl-X Protein | 1 | 2006 | 36 | 0.130 |
Why?
|
| Flow Cytometry | 4 | 2015 | 489 | 0.130 |
Why?
|
| Phenylurea Compounds | 3 | 2010 | 31 | 0.130 |
Why?
|
| Niacinamide | 3 | 2010 | 31 | 0.130 |
Why?
|
| Benzamides | 1 | 2006 | 156 | 0.130 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 33 | 0.130 |
Why?
|
| Carrier Proteins | 3 | 2003 | 597 | 0.130 |
Why?
|
| Gene Expression | 4 | 2013 | 770 | 0.120 |
Why?
|
| Male | 16 | 2015 | 37321 | 0.120 |
Why?
|
| Recombinant Proteins | 4 | 2011 | 742 | 0.120 |
Why?
|
| Cell Line | 6 | 2014 | 1752 | 0.120 |
Why?
|
| Luciferases | 2 | 2013 | 105 | 0.110 |
Why?
|
| Cycloheximide | 3 | 1998 | 50 | 0.110 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 3 | 2011 | 19 | 0.100 |
Why?
|
| Glioma | 1 | 2003 | 140 | 0.100 |
Why?
|
| Blotting, Western | 3 | 2015 | 954 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2015 | 77 | 0.100 |
Why?
|
| Cell Death | 3 | 2009 | 329 | 0.090 |
Why?
|
| Polyploidy | 1 | 2021 | 24 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 615 | 0.090 |
Why?
|
| Ligands | 4 | 2005 | 317 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 561 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2001 | 174 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2013 | 1200 | 0.090 |
Why?
|
| Lymphocyte Activation | 2 | 2014 | 397 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2011 | 40 | 0.090 |
Why?
|
| Cell Line, Transformed | 2 | 2011 | 100 | 0.090 |
Why?
|
| Embryonic Development | 1 | 2021 | 100 | 0.090 |
Why?
|
| RNA Interference | 2 | 2014 | 266 | 0.090 |
Why?
|
| Arachidonic Acid | 3 | 1996 | 86 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 710 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 371 | 0.090 |
Why?
|
| HCT116 Cells | 2 | 2010 | 63 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 1745 | 0.090 |
Why?
|
| Stromal Cells | 2 | 2014 | 113 | 0.080 |
Why?
|
| Sphingosine | 2 | 2013 | 315 | 0.080 |
Why?
|
| Melanoma | 2 | 2009 | 335 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 411 | 0.080 |
Why?
|
| Hydrogen Peroxide | 2 | 2011 | 168 | 0.080 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 2 | 2009 | 3 | 0.080 |
Why?
|
| Transfection | 4 | 2006 | 782 | 0.080 |
Why?
|
| Lymphocytes | 1 | 2009 | 228 | 0.080 |
Why?
|
| Free Radicals | 2 | 2008 | 65 | 0.080 |
Why?
|
| Adenoviridae Infections | 2 | 2012 | 6 | 0.070 |
Why?
|
| Transplantation, Heterologous | 2 | 2009 | 122 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2009 | 215 | 0.070 |
Why?
|
| Caspase 8 | 2 | 2009 | 40 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1664 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 1447 | 0.070 |
Why?
|
| Kinetics | 3 | 2005 | 1047 | 0.060 |
Why?
|
| Cell Division | 2 | 2009 | 541 | 0.060 |
Why?
|
| Endopeptidases | 1 | 1995 | 52 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2015 | 130 | 0.060 |
Why?
|
| Mitochondrial Membranes | 1 | 2014 | 45 | 0.060 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2014 | 38 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 209 | 0.060 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2014 | 35 | 0.060 |
Why?
|
| Primary Cell Culture | 1 | 2014 | 56 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 659 | 0.060 |
Why?
|
| Immunologic Memory | 1 | 2014 | 75 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2009 | 376 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 322 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 562 | 0.060 |
Why?
|
| Heat-Shock Response | 1 | 2013 | 7 | 0.060 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 58 | 0.060 |
Why?
|
| Culture Media, Conditioned | 1 | 2013 | 78 | 0.060 |
Why?
|
| Tissue Culture Techniques | 1 | 2013 | 62 | 0.060 |
Why?
|
| Mice, Inbred CBA | 1 | 2013 | 107 | 0.060 |
Why?
|
| Coculture Techniques | 1 | 2013 | 147 | 0.050 |
Why?
|
| Phospholipases A2 | 3 | 1998 | 32 | 0.050 |
Why?
|
| Adenovirus E3 Proteins | 1 | 1992 | 1 | 0.050 |
Why?
|
| Arsenites | 1 | 1992 | 8 | 0.050 |
Why?
|
| Sodium Compounds | 1 | 1992 | 10 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2000 | 2550 | 0.050 |
Why?
|
| Cytosol | 3 | 1998 | 123 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 1083 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 170 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2014 | 432 | 0.050 |
Why?
|
| Amidohydrolases | 1 | 2012 | 60 | 0.050 |
Why?
|
| Arsenic | 1 | 1992 | 46 | 0.050 |
Why?
|
| Mechanoreceptors | 1 | 2012 | 11 | 0.050 |
Why?
|
| Luminescent Proteins | 2 | 2003 | 57 | 0.050 |
Why?
|
| Lysophospholipids | 1 | 2013 | 209 | 0.050 |
Why?
|
| Dissection | 1 | 2012 | 29 | 0.050 |
Why?
|
| Endoplasmic Reticulum | 1 | 2012 | 148 | 0.050 |
Why?
|
| Mice, Inbred C3H | 3 | 1998 | 134 | 0.050 |
Why?
|
| Urine | 1 | 2011 | 47 | 0.050 |
Why?
|
| Oxidants | 1 | 2011 | 48 | 0.050 |
Why?
|
| Reactive Nitrogen Species | 1 | 2011 | 32 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2014 | 384 | 0.050 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2011 | 93 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2011 | 191 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2011 | 133 | 0.050 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2010 | 26 | 0.050 |
Why?
|
| Phosphotyrosine | 1 | 2010 | 41 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2010 | 20 | 0.050 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2010 | 4 | 0.050 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2010 | 22 | 0.050 |
Why?
|
| Hep G2 Cells | 1 | 2010 | 68 | 0.040 |
Why?
|
| Epoxy Resins | 1 | 2009 | 4 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 137 | 0.040 |
Why?
|
| Orthomyxoviridae | 1 | 2009 | 6 | 0.040 |
Why?
|
| HLA-A2 Antigen | 1 | 2009 | 18 | 0.040 |
Why?
|
| Viral Matrix Proteins | 1 | 2009 | 10 | 0.040 |
Why?
|
| Elongation Factor 2 Kinase | 1 | 2009 | 3 | 0.040 |
Why?
|
| Metalloporphyrins | 1 | 2009 | 25 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2009 | 38 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2010 | 289 | 0.040 |
Why?
|
| Beclin-1 | 1 | 2009 | 11 | 0.040 |
Why?
|
| Caspase 9 | 1 | 2009 | 31 | 0.040 |
Why?
|
| Fumonisins | 1 | 2009 | 14 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2011 | 382 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2013 | 1692 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2009 | 91 | 0.040 |
Why?
|
| Caspase Inhibitors | 1 | 2009 | 36 | 0.040 |
Why?
|
| Bortezomib | 1 | 2009 | 45 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 2009 | 112 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 134 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 114 | 0.040 |
Why?
|
| Protein Transport | 1 | 2009 | 280 | 0.040 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2007 | 17 | 0.040 |
Why?
|
| 3T3 Cells | 2 | 1998 | 124 | 0.040 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2007 | 32 | 0.040 |
Why?
|
| Iron Chelating Agents | 1 | 2007 | 31 | 0.040 |
Why?
|
| Deferoxamine | 1 | 2007 | 45 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 649 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2006 | 20 | 0.040 |
Why?
|
| Bystander Effect | 1 | 2006 | 10 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2006 | 83 | 0.030 |
Why?
|
| DNA Primers | 1 | 2006 | 302 | 0.030 |
Why?
|
| Fibroblasts | 3 | 1998 | 902 | 0.030 |
Why?
|
| Cisplatin | 1 | 2006 | 192 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2673 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2006 | 99 | 0.030 |
Why?
|
| Recoverin | 1 | 2005 | 3 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 88 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2005 | 71 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2005 | 140 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 765 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2005 | 111 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 304 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2005 | 304 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2005 | 114 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 951 | 0.030 |
Why?
|
| Phenotype | 1 | 2007 | 947 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2005 | 294 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2005 | 161 | 0.030 |
Why?
|
| Antibodies | 1 | 2005 | 241 | 0.030 |
Why?
|
| Models, Biological | 1 | 2008 | 981 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2008 | 753 | 0.030 |
Why?
|
| Astrocytoma | 1 | 2003 | 30 | 0.030 |
Why?
|
| Eye Proteins | 1 | 2005 | 160 | 0.030 |
Why?
|
| Glucose | 1 | 2005 | 307 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2003 | 246 | 0.030 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 22 | 0.030 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2002 | 22 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 848 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2002 | 39 | 0.030 |
Why?
|
| Female | 2 | 2013 | 38074 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2001 | 111 | 0.020 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 2000 | 6 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2000 | 66 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2000 | 22 | 0.020 |
Why?
|
| Genes, fos | 1 | 2000 | 22 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2003 | 431 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2000 | 29 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2000 | 114 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2000 | 337 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1998 | 22 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 1998 | 110 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 107 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2000 | 1033 | 0.020 |
Why?
|
| Tritium | 1 | 1996 | 101 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2000 | 508 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1996 | 48 | 0.020 |
Why?
|
| Fatty Acids | 1 | 1996 | 222 | 0.020 |
Why?
|
| Tosylarginine Methyl Ester | 1 | 1995 | 1 | 0.020 |
Why?
|
| Adenovirus E1A Proteins | 1 | 1995 | 6 | 0.020 |
Why?
|
| Base Sequence | 1 | 1996 | 1015 | 0.010 |
Why?
|
| Calcimycin | 1 | 1992 | 32 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1992 | 152 | 0.010 |
Why?
|
| Proteins | 1 | 1995 | 474 | 0.010 |
Why?
|